References
[1] Assimon, M. M., Flythe, J. E. (2017). Definitions of intradialytic hypotension. Semin Dial. , 2017, 30(6): 464-472.
[2] K/DOQI Workgroup. (2005). K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis., 2005, 45(4 Suppl 3): S1-153.
[3] Reeves, P. B., Mc Causland, F. R. (2018). Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension. Clin J Am Soc Nephrol. , 2018, 13(8): 1297-1303.
[4] Shoji, T., Tsubakihara, Y., Fujii, M., Imai, E. (2004). Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. , 2004 Sep, 66(3): 1212-20.
[5] Flythe, J. E., Xue, H., Lynch, K. E., Curhan. G. C., Brunelli, S. M. (2015). Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. , 2015 March, 26(3): 724-34.
[6] Mercadal, L., Petitclerc, T. (2005). Effect of mineralocorticoids on interdialytic weight gain in hemodialysis patients with perdialytic hypotension. Hemodial Int. , 2005, 9(4): 338-40.
[7] Seo, Y., Jeung, S., Kang, S. M., Yang, W. S., Kim, H., Kim, S. B. (2018). Use of fludrocortisone for intradialytic hypotension. Kidney Res Clin Pract. , 2018, 37(1): 85-88.
[8] Palma, J. A., Kaufmann, H. (2020). Management of Orthostatic Hypotension. Continuum (MinneapMinn). 2020, 26(1): 154-177.
[9] Freeman, R. (2008). Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med., 2008, 358(6): 615-24.
[10] Davies, I. B., Bannister, R. G., Sever, P. S., Wilcox, C. S. (1978). Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol. , 1978, 6(5): 444P-445P. PMID: 728295.
[11] Veazie, S., Peterson, K., Ansari, Y., Chung, K. A., Gibbons, C. H., Raj, S. R., Helfand, M. (2021). Fludrocortisone for orthostatic hypotension. Cochrane Database Syst Rev., 2021, 5(5): CD012868.
[12] Chobanian, A. V., Volicer, L., Tifft, C. P., Gavras, H., Liang, C. S., Faxon, D. (1979). Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med., 1979, 301(2): 68-73.
[13] Grijalva, C. G., Biaggioni, I., Griffin, M. R., Shibao, C. A. (2017). Fludrocortisone Is associated with a Higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc. , 2017, 6(10): e006848.
[14] Prakash, S., Garg, A. X., Heidenheim, A. P., House, A. A. (2004). Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant, 2004, 19(10): 2553-8.
[15] Proamatine (midodrine). Prescribing information 2017. Shire US Inc. Lexington, MA, USA.
[16] Hammes, M., Bakris, G. L. (2018). Intradialytic Hypotension: Is Midodrine the Answer? Am J Nephrol. , 2018, 48(5): 378-380.
[17] Brunelli, S. M., Cohen, D. E., Marlowe, G., Van Wyck, D. (2018). The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Am J Nephrol. , 2018, 48(5): 381-388.
[18] Northera (Droxidopa) prescribing information. Chelsea Therapeutics, Inc. Charlotte, NC, 2014.
[19] Akizawa, T., Koshikawa, S., Iida, N., Marumo, F., Akiba, T., Kawaguchi, Y., Imada, A., Yamazaki, C., Suzuki, M., Tubakihara. Y. (2002). Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Nephron, 2002, 90(4): 384-90.
[20] Vannorsdall, M. D., Hariachar, S., Hewitt, L. A. (2015). A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension. Postgrad Med., 2015, 127(2): 133-43.